Evidence-Based Complementary and Alternative Medicine

Evidence-Based Complementary and Alternative Medicine / 2012 / Article

Research Article | Open Access

Volume 2012 |Article ID 136527 | https://doi.org/10.1155/2012/136527

Anvarbatcha Riyasdeen, Vaiyapuri S. Periasamy, Preethy Paul, Ali A. Alshatwi, Mohammad A. Akbarsha, "Chloroform Extract of Rasagenthi Mezhugu, a Siddha Formulation, as an Evidence-Based Complementary and Alternative Medicine for HPV-Positive Cervical Cancers", Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 136527, 10 pages, 2012. https://doi.org/10.1155/2012/136527

Chloroform Extract of Rasagenthi Mezhugu, a Siddha Formulation, as an Evidence-Based Complementary and Alternative Medicine for HPV-Positive Cervical Cancers

Academic Editor: Pradeep Visen
Received16 Jun 2011
Accepted20 Jul 2011
Published27 Oct 2011


Rasagenthi Mezhugu (RGM) is a herbomineral formulation in the Siddha system of traditional medicine and is prescribed in the southern parts of India as a remedy for all kinds of cancers. However, scientific evidence for its therapeutic efficacy in cervical cancer is lacking, and it contains heavy metals. To overcome these limitations, RGM was extracted, and the fractions were tested on HPV-positive cervical cancer cells, ME-180 and SiHa. The extracts, free from the toxic heavy metals, affected the viability of both the cells. The chloroform fraction (cRGM) induced DNA damage and apoptosis. Mitochondria-mediated apoptosis was indicated. Though both the cells responded to the treatment, ME-180 was more responsive. Thus, this study brings up scientific evidence for the efficacy of RGM against the HPV-mediated cervical cancer cells and, if the toxic heavy metals are the limitation in its use, cRGM would be a suitable candidate as evidence-based complementary and alternative medicine for HPV-positive cervical cancers.

1. Introduction

Cancer is one of the major public health problems worldwide and accounts for an estimated 2.5 million cases in India alone [1]. In the wake of resistance to chemotherapy and the escalating toxic effects of synthetic drugs/compounds, all possible avenues are being explored to develop new and novel anticancer drugs that will overcome these limitations. One of the avenues is phytotherapy, which is a recognized complementary and alternative (CAM) therapeutic modality [2]. Many cancer patients, who are already crippled with this disease, and further burdened by drug-induced toxic side effects, now turn to complementary and alternative medicines hoping for a better cure or at least palliation [3]. Herbalism is a common medical practice since time immemorial. More than 60% of the approved drugs are derived from nature, and most of these discoveries were led from traditional herbal medicines [4]. The Indian traditional systems of medicine and folk medicines make use of thousands of plant-based formulations [5]. The principle underlying the use of more than one plant/plant product in these formulations is that they may produce synergistic and/or additive effects, or one may neutralize the toxic effect of another, which is otherwise therapeutic in the given context [6].

Siddha is one among the three popular Indian traditional medicinal systems, the other two being Ayurveda and Unani. Siddha medicine formulations are mostly polyherbal, but may also include metals, chemicals, and/or animal products. The common Siddha preparations are Bhasma (calcined metals and minerals), Churna (powders), Kashaya (decoctions), Lehya (confections), Ghrita (ghee), Taila (oil), and Mezhugu (wax). Rasagenthi Mezhugu (RGM), a Siddha medicine, is a formulation containing 38 different botanicals and 8 inorganic substances, some of which are heavy metals [7]. Siddha practitioners prescribe RGM as a therapy for different cancers [7]. However, scientific evidence for the therapeutic efficacy of RGM in cancer is far too limited. This is in view of the fact that the complexity of the formulation does not facilitate investigations in vitro. Also, the heavy metals in RGM, mercury, lead, and arsenic, are toxic [8]. To overcome both these limitations, a modality was developed whereupon RGM was extracted in solvents of increasing polarity, and the extracts were tested on cancer cell lines [7, 9]. The extracts were found to be free from the toxic heavy metals and amenable for in vitro testing. Thus, chloroform fraction of RGM was shown to be cytotoxic to prostate cancer cell PC3 [7] and lung cancer cells A-549 and H-460 [9], and in both cases, the cells succumbed to death by apoptosis.

Cervical cancer is one of the serious health problems in women [10]. In India alone, more than 70,000 new cases of cervical cancer are reported every year [1]. Most of the cervical cancers are caused by HPV infection and integration of HPV genome into the host cell’s genome [11]. Thus, these cervical cancers being etiologically different, it would be pertinent to find if prescription of RGM to cervical cancer patients can have a scientific backing. Therefore, we carried out this study to test the most efficacious extract of RGM, the chloroform extract, which is free from heavy metals [7, 9], on HPV-mediated cervical cancer cell lines, ME-180 and SiHa. In doing so, we focused on apoptosis as the end point, since in these cervical cancer cells, the cell cycle progression and apoptosis cascade are deregulated [12].

2. Materials and Methods

2.1. Preparation of RGM

Rasagenthi Mezhugu was obtained from Indian Medical Practitioners Co-operative Pharmacy and Stores Ltd., (IMPCOPS, Thiruvanmiyur, Chennai, India), an authoritative source of Indian medicines (http://www.impcops.org/), and its composition has been already described [7].

2.2. Extraction of RGM

The extraction procedure also has been previously described [7]. Briefly, RGM was extracted with methanol (MeOH) using Soxhlet apparatus. The MeOH phase was evaporated under reduced pressure to obtain a dark brown residue. This residue was suspended in water and extracted with four organic solvents with increasing polarity, namely, n-hexane, CHCl3, EtOAc, and n-BuOH, and the final residue was extracted in water. All five extracts were condensed into powder/paste under reduced pressure using a rotary evaporator (Buchi Labortechnik AG, Flawil, Switzerland).

2.3. Cell Culture

Human cervical cancer cells ME-180 and SiHa were obtained from National Center for Cell Science (NCCS), Pune, India. The cells were maintained in DMEM medium supplemented with 10% FBS (Sigma-Aldrich, St. Louis, Mo, USA), and with 100 U/mL penicillin and 100 μg/mL streptomycin as antibiotics (Himedia, Mumbai, India) in a humidified atmosphere of 5% CO2 and 95% air in a CO2 incubator (Heraeus, Hanau, Germany).

2.4. Cell Viability Assay

All five RGM extracts, in the concentration range of 0–500 μg/mL, dissolved in DMSO (Sigma-Aldrich), were added to the wells, 24 h after seeding of 5 × 103 cells per well of 96-well plate. DMSO was used as the solvent control. After 24 and 48 h of incubation, 20 μL of MTT solution (5 mg/mL in phosphate-buffered saline (PBS)) was added to each well, and the plates were wrapped with aluminum foil and incubated for 4 h at 37°C. The purple formazan product was dissolved by addition of 100 μL of 100% DMSO to each well. The absorbance was monitored at 570 nm (measurement) and 630 nm (reference) using a 96-well plate reader (Bio-Rad, Hercules, Calif, USA). Data were collected for four replicates each and used to calculate the means and the standard deviations. The percentage inhibition was calculated from this data using the following formula: From the values thus obtained, the IC50 for the respective extracts, and for the respective durations of treatment, that is, 24 and 48 h, was deduced from the curves obtained by plotting percentage inhibition against concentration. Since the MTT test indicated that the chloroform extract of RGM was the most efficacious among the five extracts, and it affected the viability of the cells at concentrations very low compared to the others, subsequent studies were limited to this extract (cRGM).

2.5. Hoechst 33528 Staining

The cervical cancer cells ME-180 and SiHa were cultured in 6-well plates and treated with IC50 concentration of cRGM. After 24 and 48 h incubation, the treated and untreated cells were harvested and stained with Hoechst 33258 (1 mg/mL, aqueous) for 5 min at room temperature. A drop of cell suspension was placed on a glass slide, and a cover slip was laid over to reduce light diffraction. At random 300 cells, in duplicate, were observed at ×400 in a fluorescent microscope (Carl Zeiss, Jena, Germany) fitted with a 377–355 nm filter, and the percentage of cells reflecting pathological changes was calculated.

2.6. Acridine Orange (AO) and Ethidium Bromide (EB) Fluorescent Assay for Cell Death

Acridine orange (AO) and ethidium bromide (EB) staining was performed as described by Spector et al. [13]. The cells were cultured in 6-well plates and treated with IC50 concentration of cRGM for 24 and 48 h. The treated and untreated cells (25 μL of suspension containing 5  ×  105 cells) were incubated with acridine orange and ethidium bromide solution (1 part of 100 μg/mL acridine orange and 1 part of 100 μg/mL ethidium bromide in PBS) and examined in the fluorescent microscope using a UV filter (450–490 nm). Three hundred cells per sample were counted, in duplicate, for each time point (24, 48 h). The cells were scored as viable or dead, and if dead, whether by apoptosis or necrosis as judged from nuclear morphology and cytoplasmic organization. The percentages of apoptotic and necrotic cells were then calculated. Morphological features of interest were photographed.

2.7. Single-Cell Gel Electrophoresis (Comet Assay)

DNA damage was detected by adopting the comet assay [14]. Treated (IC50 concentration; 24 and 48 h treatment) and control cells were suspended in low-melting-point agarose in PBS and pipetted on to microscope slides precoated with a layer of normal-melting-point agarose. The slides were chilled on ice for 10 min and then immersed in lysis solution (2.5 M NaCl, 100 × 10−3 M Na2EDTA, 10 × 10−3 M Tris, 0.2 × 10−3 M NaOH, pH 10.01, and Triton X-100), and the solution was kept overnight at 4°C in order to lyse the cells and to permit DNA unfolding. The slides were then exposed to alkaline buffer (300 × 10−3 M NaOH, 1 × 10−3 M Na2EDTA, pH > 13) for 20 min to allow DNA unwinding. The slides were washed with buffer (0.4 M Tris, pH 7.5) to neutralize excess alkali and to remove detergents, before staining with EB. Photomicrographs were obtained using the fluorescent microscope. One hundred cells, in duplicate, from each treatment group were digitalized and analyzed using Comet Assay Software Program (CASP). The images were used to estimate the DNA content of individual nuclei and to evaluate the degree of DNA damage that represented the fraction of total DNA in the tail.

2.8. Assay for Mitochondrial Transmembrane Potential

Mitochondrial transmembrane potential was assessed using the fluorescent probe JC-1, which produces green fluorescence in the cytoplasm and red-orange fluorescence when accumulated in healthy mitochondria. In case the mitochondrial membrane potential is affected, JC1 will be limited to cytoplasm, and the whole cell will fluoresce green. The cells were grown in six well plates and treated with IC50 concentration of cRGM. After 12 and 24 h exposure, the cells were stained for 30 min with JC-1 (2 μg/mL) in the culture medium. The adherent cell layer was then washed with PBS and lifted using 250 μL of trypsinEDTA. The cells were collected in PBS, washed by centrifugation, resuspended in 0.3 mL of PBS, mixed gently, and examined in the fluorescent microscope using a UV filter (450–490 nM). The specific fluorescent patterns were indicative of intact (red fluorescence) or loss (green fluorescence) of mitochondrial transmembrane potential (ΔΨm).

2.9. Annexin V-Cy3 Apoptosis Assay

Phosphatidylserine translocation from inner to outer leaflet of the plasma membrane is one of the early features of apoptosis. Cell surface phosphatidylserine was detected using phosphatidylserine-binding protein annexin V conjugated with Cy3 using the commercially available annexin V-Cy3 apoptosis detection kit (APOAC, Apoptosis Detection Kit, Sigma, Calif, USA). The cells were treated with IC50 concentration of cRGM. After 12 and 24 h incubation, the cells were harvested, centrifuged, and pellets were collected. The cell pellet was washed with PBS and then with 1x binding buffer. The washed cell pellet was suspended in 50 μL of double-label staining solution (Ann-Cy3 and 6-CFDA) and kept in dark for 10 min. After the incubation, the excess label was removed by washing the cells with 1x binding buffer. The annexin-Cy3 and 6-CFDA-labelled cells were observed in the fluorescent microscope. 300 cells at random were observed. This assay facilitated detection of live cells (green), necrotic cells (red), and apoptotic cells (red nuclei and green cytoplasm). The percentage of cells reflecting cell death (apoptotic and necrotic, separately) was calculated. Data were collected from two individual experiments, each in duplicate, and used to calculate the respective means and the standard deviations.

2.10. Statistics

Numerical data are expressed as mean ± standard deviation (SD). Statistical differences were evaluated by a one-way analysis of variance (ANOVA) using statistical package for social sciences (SPSS) software for window9 Version 11.5 (SPSS) Inc., Chicago, Ill, USA). Posthoc test was performed for comparisons using the least significant difference (LSD) test. Differences were considered statistically significant when .

3. Results

3.1. Effect of cRGM on Viability of Cells as Revealed in MTT Assay

MTT assay determines the integrity of mitochondria and reflects the viability or otherwise of the cells. The results of MTT assay showed that although all extracts of cRGM, other than water extract, inhibited proliferation of both SiHa and ME-180 cervical cancer cells in time- and dose-dependent manner, cRGM was the most efficacious since it affected viability of the cells at a concentration many times lesser than the others (Table 1). Of the two cell types subjected to the test, ME-180 was more responsive than SiHa. Therefore, the rest of the study was limited to cRGM.

IC50 (μg/mL)
RGM extract SiHa cells ME-180 cells
24 h 48 h 24 h 48 h

Ethyl acetate

3.2. Changes in Nucleus and Chromatin as Revealed in Hoechst Staining

Hoechst 33528 staining showed that there were significant changes in the chromatin of treated cells. In the untreated cells, the nuclei were round, even, and homogenous, and the chromatin was intact. After treatment with cRGM for 24 and 48 h, the intensity of blue fluorescence emittance in respect of the treated cells was much brighter than the control cells, and changes in the chromatin such as condensation, marginalization, and fragmentation were observed (Figure 1).

The nuclei were found to be abnormal in 31% and 54% of cRGM-treated SiHa cells in the 24, 48 h treatment groups, respectively. In the case of ME-180 cell, the impact was much higher, since 45% and 61% of cells were affected during 24 and 48 h treatment, respectively (Figure 2)

3.3. Apoptotic versus Necrotic Death Caused by the Treatment

The results obtained with AO & EB double staining of control and treated cells are presented in the Figure 3. The control cells fluoresced uniformly green and had normal features. Most of the cells treated with cRGM fluoresced red and indicated apoptotic features such as cell shrinkage, chromatin condensation, nuclear fragmentation and apoptotic body formation. A few cells indicated necrotic features such as cell swelling and lysis. Though both SiHa and ME-180 cells responded with higher incidence of apoptosis than necrosis, the incidence of necrosis was higher in SiHa than ME-180 cells (Figure 4).

3.4. DNA Damage as Revealed in Single Cell Gel Electrophoresis

In order to find if the treatment brings about DNA damage, which is an early event in apoptosis, single cell gel electrophoresis (Comet assay) was conducted. After staining with ethidium bromide and observation under fluorescent microscope (Figure 5), the cells were scored as dead, highly damaged, damaged, slightly damaged and intact, and histograms were prepared using the Comet Analysis Software (CASP) (Figure 6). The chromatin content in the nuclear head, the length of the comet tail, and other comet parameters were recorded for 100 individual cells, and the concurrent comparative data were generated. Though the treatment caused DNA damage to both the cell types, the response was higher in ME-180 cell than SiHa cell.

3.5. Effect of cRGM on Mitochondrial Transmembrane Potential

The mitochondrial permeability transition is an important step in the induction of cellular apoptosis. The mitochondrial membrane potential was detected using the unique fluorescent cationic dye, JC-1. The cRGM-treated cells showed progressive loss of red JC-aggregate fluorescence, and appearance of green monomer fluorescence in the cytoplasm at 12 h, and complete loss of red fluorescence presence of only green fluorescence at 24 h (Figure 7).

3.6. Annexin V-Cy3 Assay

A well-established feature of an early event in apoptosis is externalization of phosphatidyl serine (PS) from inner to outer leaflet of plasma membrane. The results obtained with Annexin V binding assay of control and treated cells are represented in Figure 8. Treatment of SiHa cells with cRGM caused 25 and 33% of cells to succumb to apoptosis during 12 and 24 h treatment, respectively. In the case of ME-180 cell, the corresponding values were higher, 43 and 54%, respectively (Figure 9). In both cell types, a small percentage indicated reflections of necrosis, and the incidence was higher with SiHa than ME 180 cells.

4. Discussion

Since ancient times, plant-based formulations have been practiced as remedies against diverse ailments [15]. Over the past two decades, interest in traditional medicines has increased considerably in many parts of the world [16]. The Indian systems of medicine in general, and Ayurveda and Siddha in particular, which originated several centuries ago, are holistic approaches to healthcare, and RGM is one of the few commonly prescribed medicines for cancer in the Siddha system. The aim of this study was to find if the chloroform extract of RGM, which is not only free from the toxic heavy metal ingredients (which are removed during the extraction process) but amenable for in vitro testing, and one which has been already shown to be cytotoxic to PC3, A-549, and H-460 cancer cells, would be cytotoxic to HPV-positive cervical cancer cells, and if so to infer the possible mechanism of action.

The outcome of cytotoxicity assay in this study clearly shows that cRGM is cytotoxic to both the HPV-positive cervical cancer cells and produced the effect in very low doses compared to the other extracts, as has been the case with the prostate [7] and lung [9] cancer cells. An earlier study made a preliminary HPLC analysis of cRGM and found about 40–50 compounds in it [7]. Such heterogeneity would provide for the possibility of synergistic and/or additive interactions between the compounds, the sources of which are from the different herbals. Synergism, particularly, is important because it allows lower and safer doses of each compound. Most direct-acting natural compounds, if used alone, would require excessive and unsafe doses to inhibit cancer [17]. The data obtained in this study strongly suggest that, when used in combination, natural compounds can potentially produce synergistic effects in vitro. Natural compounds can be divided into three groups: those that inhibit cancer cell proliferation directly, those that act by indirect means to inhibit cancer progression, and those that stimulate the immune system [17]. There is evidence in the scientific literature that the herbals in RGM possess properties such as anticancer, antioxidant, detoxification, and immune modulation. Specifically, the following herbals possess one or more of these property/properties: Acorus calamus [18, 19]; Alpinia galangal [20]; Azima tetracantha [21]; Celastrus paniculatus [22]; Cinnamomum zeylanicum [23, 24]; Clerodendron serratum [25]; Cocos nucifera [26]; Cuminum cyminum [27]; Curcuma longa [3, 28]; Elettaria cardamomum [24, 29]; Embelia ribes [30, 31]; Foeniculum vulgare [32, 33]; Hygrophila auriculata [34]; Myristica fragrans [35]; Nigella sativa [3, 36, 37]; Piper longum [38]; Piper nigrum [39]; Plumbago zeylanica [40, 41]; Psoralea corylifolia [42]; Quercus infectoria [43]; Saussurea lappa [44]; Semecarpus anacardium [3, 45, 46]; Sesamum indicum [47]; Smilax china [48, 49]; Strychnos nux-vomica [50, 51]; Strychnos potatorum [52]; Terminalia chebula [53, 54]; Trachyspermum ammi [55]; Vernonia anthelmintica [56]; Vitis vinifera [57]; Withania somnifera [58]; Zingiber officinale [5961]. Thus, cRGM presents a strong case for synergism as well as additivism of the multiplicity of compounds from the 38 herbals, most of which have been scientifically proven as associated with one or more aspects of interference with cancer.

The idea that an integrated approach is needed to manage cancer using the growing body of knowledge gained through scientific developments [3] is adequately taken care of in our approach of herbal medicine to cancer. Our finding is to be viewed in the background that synergistic interactions occur within a total extract of a single herb, as well as between different herbs in a formulation [62]. In fact, the formulations of traditional medicines used in China, India, and Japan have been constructed to expect desirable treatment of diseases. The principles are based on the interaction of several crude drugs or several ingredients even in a single crude drug. Therefore, the apparent combined effects are equivalent to the sum of effects of those components which underwent addition, potentiation, subtraction, and modulation [63].

Phytotherapy, the therapeutic efficacy of which is based on the combined action of a mixture of constituents, offers new treatment opportunities. Because of their biological defense function, plant secondary metabolites act by targeting and disrupting the cell membrane, by binding and inhibiting specific proteins or they adhere to or intercalate into RNA or DNA [64]. Cancer, by etiology, is multifactorial in origin and, hence, it is only logical that multiple drugs are used at a time.

The focus of the present study has been to find if cRGM would inhibit the proliferation of and induce apoptosis in HPV-positive cervical cancer cells, because these are the two major goals in cancer treatment [9]. This study provides evidence in support of the mode of cell death is essentially apoptosis is revealed in features such as chromatin condensation, nuclear fragmentation, and formation of apoptotic bodies. DNA fragmentation is one of the major events in apoptosis. The result of comet assay strongly suggests that cRGM brings about strand breaks in DNA of the cervical cancer cells. The mitochondrial permeability transition is an important step in the induction of cellular apoptosis, and the results clearly suggest that cRGM leads to collapse of the mitochondrial transmembrane potential in cervical cancer cells. This collapse is thought to occur through formation of pores in the mitochondria by dimerized Bax or activated Bid, Bak, or Bad proteins. Activation of these proapoptotic proteins is accompanied by release of cytochrome c into the cytoplasm, which would promote the activation of caspases which are directly responsible for apoptosis [65]. The phosphatidyl serine (PS) expression on the outer leaflet of plasma membrane was detected with annexinV-Cy3 binding, confirming the early stage of apoptosis. Based on the mitochondrial transmembrane potential depolarization assessment, it is reasonable to conclude that cRGM induces apoptosis through the mitochondria-mediated pathway. Study in the future to examine the proteins regulating mitochondria-mediated apoptosis pathway, such as cytochrome c, Apaf-1, adenosine triphosphate, caspase-9, caspase-8, caspase-3, and IAP, will be highly relevant

Cervical cancer takes the lives of more than 250,000 women each year globally [66], and most of the cervical cancers are associated with human papilloma virus (HPV) infection [67]. The HPV 16 and 18 oncoproteins E6 and E7 cause immortalization of the infected cells by interacting with and degrading p53 and the cell cycle regulator proteins such as Rb, p21, and p27 [68, 69]. Since cRGM is highly efficient in inducing death of HPV-positive cervical cancer cells, it could be speculated that the extract might restore p53 and the cell cycle regulatory proteins to functional status by causing degradation of viral onco-proteins, which is worthy of investigation.

The major limitations of the Indian traditional medicines in presence of one or more toxic heavy metals in the preparations, some intentionally included in view of proprietary prescription in the original formulation (as in RGM), and/or presence of toxic heavy metals to unknown levels in the herbals that are present in the drug. As far as the first is concerned, it is an established fact that the original prescription requires thorough processing of the metal that detoxifies the metal and makes it into a therapeutic substance [70]. In the recent times, there is a concept that the treatments, to which the metals are subjected to make them into nanoparticles [70]. There is evidence that it is potentially toxic when, macro- or microparticles, heavy metal could be nontoxic and therapeutic when made into nanoparticles [71]. It is unfortunate that some quacks try to economize on the preparation and so do not adopt the prescribed procedures [72]. The presence of heavy metals in the herbal ingredients could be overcome through stringent quality control measures [72]. Even assuming that the heavy metals, present in whatever form, are not acceptable, the present study and a few earlier studies [7, 9] show that, in spite of the limitation of deviating from the holism of the proprietary drug formulation which Regulatory Authorities of Indian systems of medicine may object to, even after extracting out the heavy metals RGM in the chloroform extract is potent enough to deal with cancers, especially prostate, lung, and cervical.

5. Conclusion

The original RGM formulation, if exonerated of heavy metal toxicity, or cRGM, which is free from heavy metals, would be a potential evidence-based complementary and alternative medicine for HPV-positive cervical cancers.


The financial assistance from CSIR, Government. of India, New Delhi to M. A. Akbarsha (Grant no. 37(1223)/05/EMR-II) and A. Riyasdeen (Senior Research Fellow, 09/475(0163)/2010-EMR-1) is gratefully acknowledged.


  1. K. U. Devi, “Current status of gynecological cancer care in India,” Journal of Gynecologic Oncology, vol. 20, no. 2, pp. 77–80, 2009. View at: Publisher Site | Google Scholar
  2. S. A. Kang, H. J. Park, M. J. Kim, S. Y. Lee, S. W. Han, and K. H. Leem, “Citri Reticulatae Viride Pericarpium extract induced apoptosis in SNU-C4, human colon cancer cells,” Journal of Ethnopharmacology, vol. 97, no. 2, pp. 231–235, 2005. View at: Publisher Site | Google Scholar
  3. P. Balachandran and R. Govindarajan, “Cancer-an ayurvedic perspective,” Pharmacological Research, vol. 51, no. 1, pp. 19–30, 2005. View at: Publisher Site | Google Scholar
  4. A. B. da Rocha, R. M. Lopes, and G. Schwartsmann, “Natural products in anticancer therapy,” Current Opinion in Pharmacology, vol. 1, no. 4, pp. 364–369, 2001. View at: Publisher Site | Google Scholar
  5. S. Verma and S. P. Singh, “Current and future status of herbal medicines,” Veterinary World, vol. 1, no. 11, pp. 347–350, 2008. View at: Google Scholar
  6. X. K. Li, M. Motwani, W. Tong, W. Bornmann, and G. K. Schwartz, “Huanglian: a Chinese herbal extract, inhibits cell growth by suppressing the expression of cyclin B1 and inhibiting CDC2 kinase activity in human cancer cells,” Molecular Pharmacology, vol. 58, no. 6, pp. 1287–1293, 2000. View at: Google Scholar
  7. R. S. Ranga, R. Girija, M. Nur-e-alam et al., “Rasagenthi lehyam (RL) a novel complementary and alternative medicine for prostate cancer,” Cancer Chemotherapy and Pharmacology, vol. 54, no. 1, pp. 7–15, 2004. View at: Publisher Site | Google Scholar
  8. P. J. Landrigan, “Occupational and community exposures to toxic metals: lead, cadmium, mercury and arsenic,” The Western Journal of Medicine, vol. 137, no. 6, pp. 531–539, 1982. View at: Google Scholar
  9. R. Ranga, S. Sowmyalakshmi, R. Burikhanov, M. A. Akbarsha, and D. A. Chendil, “Herbal medicine for the treatment of lung cancer,” Molecular and Cellular Biochemistry, vol. 280, no. 1-2, pp. 125–133, 2005. View at: Publisher Site | Google Scholar
  10. N. P. Capps, A. Stewart, and C. Burns, “The interplay between secondhand cigarette smoke, genetics, and cervical cancer: a review of the literature,” Biological Research for Nursing, vol. 10, no. 4, pp. 392–399, 2009. View at: Publisher Site | Google Scholar
  11. R. Raybould, A. Fiander, and S. Hibbitts, “Human papillomavirus integration and its role in cervical malignant progression,” The Open Clinical Cancer Journal, vol. 5, pp. 1–7, 2011. View at: Google Scholar
  12. S. Kasibhatla and B. Tseng, “Why target apoptosis in cancer treatment,” Molecular Cancer Therapeutics, vol. 2, no. 6, pp. 573–580, 2003. View at: Google Scholar
  13. D. L. Spector, R. D. Goldman, and L. A. Leinwand, Cell: A Laboratory Manual. Culture and Biochemical Analysis of Cells, vol. 1, Cold Spring Harbor Laboratory, New York, NY, USA, 1998.
  14. N. P. Singh, M. T. MacCoy, R. R. Tice, and E. L. Schneider, “A simple technique for quantitation of low levels of DNA damage in individual cells,” Experimental Cell Research, vol. 175, no. 1, pp. 184–191, 1988. View at: Google Scholar
  15. Y. A. Ahirrao and D. A. Patil, “Indigenous healthcare practices in Bhidhana district (Maharashtra),” Indian Journal of Natural Products and Resources, vol. 1, no. 1, pp. 85–88, 2010. View at: Google Scholar
  16. C. Muthu, M. Ayyanar, N. Raja, and S. Ignacimuthu, “Medicinal plants used by traditional healers in Kancheepuram District of Tamil Nadu, India,” Journal of Ethnobiology and Ethnomedicine, vol. 2, p. 43, 2009. View at: Google Scholar
  17. J. Boik, Natural Compounds in Cancer Chemotherapy, vol. 4-5, Oregon Medical Press, New York, NY, USA, 2001.
  18. S. Mehrotra, K. P. Mishra, R. Maurya et al., “Anticellular and immunosuppressive properties of ethanolic extract of Acorus calamus rhizome,” International Immunopharmacology, vol. 3, no. 1, pp. 53–61, 2003. View at: Publisher Site | Google Scholar
  19. S. Manikandan and R. S. Devi, “Antioxidant property of α-asarone against noise-stress-induced changes in different regions of rat brain,” Pharmacological Research, vol. 52, no. 6, pp. 467–474, 2005. View at: Publisher Site | Google Scholar
  20. M. A. S. Kumar, M. Nair, P. S. Hema, J. Mohan, and T. R. Santhoshkumar, “Pinocembrin triggers Bax-dependent mitochondrial apoptosis in colon cancer cells,” Molecular Carcinogenesis, vol. 46, no. 3, pp. 231–241, 2007. View at: Publisher Site | Google Scholar
  21. T. N. Begum, M. H. M. Ilyas, S. Kalavathy, A. V. Anadh, S. Kumar, and R. Senthil, “Effects of ethanolic leaf extract of Azim tetracantha Lam. on Ehrlich ascites carcinoma tumour bearing mice,” Research Journal of Medicine and Medical sciences, vol. 4, no. 2, pp. 351–354, 2009. View at: Google Scholar
  22. M. F. Ramadan, S. G. Kinni, L. N. Rajanna, Y. N. Seetharam, M. Seshagiri, and J. T. Morsel, “Fatty acids, bioactive lipids and radical scavenging activity of Celastrus paniculatus Willd. seed oil,” Scientia Horticulturae, vol. 123, no. 1, pp. 104–109, 2009. View at: Publisher Site | Google Scholar
  23. J. M. Filho, K. A. Koiij, D. A. Mancini, F. F. Cozzolino, and R. P. Torres, “Antioxidant activity of cinnamon (cinnamomum zeylanicum, Breyne) extracts,” Bollettino Chimico Farmaceutico, vol. 137, no. 11, pp. 443–447, 1998. View at: Google Scholar
  24. S. Bhattacharjee, T. Rana, and A. Sengupta, “Inhibition of lipid peroxidation and enhancement of GST activity by cardamom and cinnamon during chemically induced colon carcinogenesis in swiss albino mice,” Asian Pacific Journal of Cancer Prevention, vol. 8, no. 4, pp. 579–582, 2007. View at: Google Scholar
  25. N. Narayanan, P. Thirugnanasambantham, S. Viswanathan, V. Vijayasekaran, and E. Sukumar, “Antinociceptive, anti-inflammatory and antipyretic effects of ethanol extract of Clerodendron serratum roots in experimental animals,” Journal of Ethnopharmacology, vol. 65, no. 3, pp. 237–241, 1999. View at: Publisher Site | Google Scholar
  26. N. Nalini, V. Manju, and V. P. Menon, “Effect of coconut cake on the bacterial enzyme activity in 1,2-dimethyl hydrazine induced colon cancer,” Clinica Chimica Acta, vol. 342, no. 1-2, pp. 203–210, 2004. View at: Publisher Site | Google Scholar
  27. Gagandeep, S. Dhanalakshmi, E. Mendiz, A. R. Rao, and R. K. Kale, “Chemopreventive effects of Cuminum cyminum in chemically induced forestomach and uterine cervix tumors in murine model systems,” Nutrition and Cancer, vol. 47, no. 2, pp. 171–180, 2003. View at: Publisher Site | Google Scholar
  28. A. B. Kunnumakkara, P. Anand, and B. B. Aggarwal, “Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins,” Cancer Letters, vol. 269, no. 2, pp. 199–225, 2008. View at: Publisher Site | Google Scholar
  29. A. F. Majdalawieh and R. I. Carr, “In vitro investigation of the potential immunomodulatory and anti-cancer activities of black pepper (Piper nigrum) and cardamom (Elettaria cardamomum),” Journal of Medicinal Food, vol. 13, no. 2, pp. 371–381, 2010. View at: Google Scholar
  30. K. H. M. Swamy, V. Krishna, K. Shankarmurthy et al., “Wound healing activity of embelin isolated from the ethanol extract of leaves of Embelia ribes Burm,” Journal of Ethnopharmacology, vol. 109, no. 3, pp. 529–534, 2007. View at: Publisher Site | Google Scholar
  31. M. Sreepriya and G. Bali, “Chemopreventive effects of embelin and curcumin against N-nitrosodiethylamine/phenobarbital-induced hepatocarcinogenesis in Wistar rats,” Fitoterapia, vol. 76, no. 6, pp. 549–555, 2005. View at: Publisher Site | Google Scholar
  32. M. Oktay, G. lhami, and O. K. Irfan, “Determination of in vitro antioxidant activity of fennel (Foeniculum vulgare) seed extracts,” Lebensmittel-Wissenschaft und-Technologie, vol. 36, no. 2, pp. 263–271, 2003. View at: Publisher Site | Google Scholar
  33. R. Guimaraes, L. Barros, A. M. Carvalho, and I. C. F. R. Ferreira, “Infusions and decoctions of mixed herbs used in folk medicine: synergism in antioxidant potential,” Phytotherapy Research, vol. 25, no. 8, pp. 1209–1211, 2011. View at: Publisher Site | Google Scholar
  34. S. J. Uddin, I. D. Grice, and E. Tiralongo, “Cytotoxic effects of Bangladeshi medicinal plant extracts,” Evidence-based Complementary and Alternative Medicine, vol. 2011, Article ID 578092, 7 pages, 2011. View at: Publisher Site | Google Scholar
  35. S. P. Hussain and A. R. Rao, “Chemopreventive action of mace (Myristica fragrans, Houtt) on methylcholanthrene-induced carcinogenesis in the uterine cervix in mice,” Cancer Letters, vol. 56, no. 3, pp. 231–234, 1991. View at: Publisher Site | Google Scholar
  36. E. S. A. Arafa, Q. Zhu, Z. Shah et al., “Thymoquinone up-regulates PTEN expression and induces apoptosis in doxorubicin-resistant human breast cancer cells,” Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, vol. 706, no. 1-2, pp. 28–35, 2011. View at: Publisher Site | Google Scholar
  37. S. Rooney and M. F. Ryan, “Effects of α-hederin and thymoquinone, constituents of Nigella sativa, on human cancer cell lines,” Anticancer Research, vol. 25, no. 3, pp. 2199–2204, 2005. View at: Google Scholar
  38. E. S. Sunila and G. Kuttan, “Immunomodulatory and antitumor activity of Piper longum Linn. and piperine,” Journal of Ethnopharmacology, vol. 90, no. 2-3, pp. 339–346, 2004. View at: Publisher Site | Google Scholar
  39. R. S. Vijayakumar, D. Surya, and N. Nalini, “Antioxidant efficacy of black pepper (Piper nigrum L.) and piperine in rats with high fat diet induced oxidative stress,” Redox Report, vol. 9, no. 2, pp. 105–110, 2004. View at: Publisher Site | Google Scholar
  40. N. T. Nguyen, H. Malonne, P. Duez, R. V. Fastre, M. Vanhaelena, and J. Fontaine, “Cytotoxic constituents from Plumbago zeylanica,” Fitoterapia, vol. 75, no. 5, pp. 500–504, 2004. View at: Publisher Site | Google Scholar
  41. R. Gomathinayagam, S. Sowmyalakshmi, F. Mardhatillah, R. Kumar, M. A. Akbarsha, and C. Damodaran, “Anticancer mechanism of plumbagin, a natural compound, on non-small cell lung cancer cells,” Anticancer Research, vol. 28, no. 2, pp. 785–792, 2008. View at: Google Scholar
  42. W. Mar, K. H. Je, and E. Seo, “Cytotoxic constituents of Psoralea corylifolia,” Archives of Pharmacal Research, vol. 24, no. 3, pp. 211–213, 2001. View at: Google Scholar
  43. G. Kaur, M. Athar, and M. S. Alam, “Quercus infectoria galls possess antioxidant activity and abrogates oxidative stress-induced functional alterations in murine macrophages,” Chemico-Biological Interactions, vol. 171, no. 3, pp. 272–282, 2008. View at: Publisher Site | Google Scholar
  44. S. G. Ko, S. H. Koh, C. Y. Jun, C. G. Na, H. S. Bae, and M. K. Shin, “Induction of apoptosis by Saussurea lappa and Pharbitis nil on AGS gastric cancer cells,” Biological & Pharmaceutical Bulletin, vol. 27, no. 10, pp. 1604–1610, 2004. View at: Publisher Site | Google Scholar
  45. P. Mathivadhani, P. Shanthi, and P. Sachdanandam, “Apoptotic effect of Semecarpus anacardium nut extract on T47D breast cancer cell line,” Cell Biology International, vol. 31, no. 10, pp. 1198–1206, 2007. View at: Publisher Site | Google Scholar
  46. R. P. K. Nair, S. J. Melnick, S. F. Wnuk, M. Rapp, E. Escalon, and C. Ramachandran, “Isolation and characterization of an anticancer catechol compound from Semecarpus anacardium,” Journal of Ethnopharmacology, vol. 122, no. 3, pp. 450–456, 2009. View at: Publisher Site | Google Scholar
  47. K. P. Suja, A. Jayalekshmy, and C. Arumughan, “Free radical scavenging behavior of antioxidant compounds of Sesame (Sesamum indicum L.) in DPPH system,” Journal of Agricultural and Food Chemistry, vol. 52, no. 4, pp. 912–915, 2004. View at: Publisher Site | Google Scholar
  48. L. S. Wu, X. J. Wang, H. Wang, H. W. Yang, A. Q. Jia, and Q. Ding, “Cytotoxic polyphenols against breast tumor cell in Smilax china L.,” Journal of Ethnopharmacology, vol. 130, no. 3, pp. 460–464, 2010. View at: Publisher Site | Google Scholar
  49. W. Xu, J. Liu, C. Li, H. Z. Wu, and Y. W. Liu, “Kaempferol-7-O-β-d-glucoside (KG) isolated from Smilax china L. rhizome induces G2/M phase arrest and apoptosis on HeLa cells in a p53-independent manner,” Cancer Letters, vol. 264, no. 2, pp. 229–240, 2008. View at: Publisher Site | Google Scholar
  50. X. K. Deng, W. Yin, W. D. Li et al., “The anti-tumor effects of alkaloids from the seeds of Strychnos nux-vomica on HepG2 cells and its possible mechanism,” Journal of Ethnopharmacology, vol. 106, no. 2, pp. 179–186, 2006. View at: Publisher Site | Google Scholar
  51. X. Deng, F. Yin, X. Lu, B. Cai, and W. Yin, “The apoptotic effect of brucine from the seed of Strychnos nux-vomica on human hepatoma cells is mediated via Bcl-2 and Ca2+ involved mitochondrial pathway,” Toxicological Sciences, vol. 91, no. 1, pp. 59–69, 2006. View at: Publisher Site | Google Scholar
  52. E. Sanmugapriya and S. Venkataraman, “Studies on hepatoprotective and antioxidant actions of Strychnos potatorum Linn. seeds on CCl4-induced acute hepatic injury in experimental rats,” Journal of Ethnopharmacology, vol. 105, no. 1-2, pp. 154–160, 2006. View at: Publisher Site | Google Scholar
  53. A. Saleem, M. Husheem, P. Harkonen, and K. Pihlaja, “Inhibition of cancer cell growth by crude extract and the phenolics of Terminalia chebula retz. fruit,” Journal of Ethnopharmacology, vol. 81, no. 3, pp. 327–336, 2002. View at: Publisher Site | Google Scholar
  54. H. S. Lee, H. N. Won, K. M. Kim, H. Lee, W. Jun, and K. W. Lee, “Antioxidant effects of aqueous extract of Terminalia chebula in vivo and in vitro,” Biological & Pharmaceutical Bulletin, vol. 28, no. 2, pp. 1639–1644, 2005. View at: Publisher Site | Google Scholar
  55. R. Velazhahan, S. Vijayanandraj, A. Vijayasamundeeswari et al., “Detoxification of aflatoxins by seed extracts of the medicinal plant, Trachyspermum ammi (L.) Sprague ex Turrill—Structural analysis and biological toxicity of degradation product of aflatoxin G1,” Food Control, vol. 21, no. 5, pp. 719–725, 2010. View at: Publisher Site | Google Scholar
  56. L. I. Hongjian, L. I. Linlin, S. Li, and S. Jing, “Effect of Vernonia anthelmintica willd extract on inhibiting the proliferation of melanoma A375 cells,” Northwest Pharmaceutical Journal, p. 01, 2008. View at: Google Scholar
  57. D. Stagos, G. Kazantzoglou, P. Magiatis, S. Mitaku, K. Anagnostopoulos, and D. Kouretas, “Effects of plant phenolics and grape extracts from Greek varieties of Vitis vinifera on Mitomycin C and topoisomerase I-induced nicking of DNA,” Journal of Molecular Medicine, vol. 15, no. 6, pp. 1013–1022, 2005. View at: Google Scholar
  58. R. Mathur, S. K. Gupta, N. Singh, S. Mathur, V. Kochupillai, and T. Velpandian, “Evaluation of the effect of Withania somnifera root extracts on cell cycle and angiogenesis,” Journal of Ethnopharmacology, vol. 105, no. 3, pp. 336–341, 2006. View at: Publisher Site | Google Scholar
  59. N. Nigam, K. Bhui, S. Prasad, J. George, and Y. Shukla, “[6]-Gingerol induces reactive oxygen species regulated mitochondrial cell death pathway in human epidermoid carcinoma A431 cells,” Chemico-Biological Interactions, vol. 181, no. 1, pp. 77–84, 2009. View at: Publisher Site | Google Scholar
  60. S. K. Katiyar, R. Agarwal, and H. Mukhtar, “Inhibition of tumor promotion in SENCAR mouse skin by ethanol extract of Zingiber officinale Rhizome,” Cancer Research, vol. 56, no. 5, pp. 1023–1030, 1996. View at: Google Scholar
  61. I. Stoilova, A. Krastanov, A. Stoyanova, P. Denev, and S. Gargova, “Antioxidant activity of a ginger extract (Zingiber officinale),” Food Chemistry, vol. 102, no. 2, pp. 764–770, 2007. View at: Publisher Site | Google Scholar
  62. E. M. Williamson, “Synergy and other interactions in phytomedicines,” Phytomedicine, vol. 8, no. 5, pp. 401–409, 2001. View at: Google Scholar
  63. I. Kimura and H. Tsuneki, “Theoretical pharmacological effects in single herb and polyherbal therapies: influences of processing on the constituents, and their synergistic/modulatory interactions,” Journal of Traditional Medicines, vol. 22, no. 1, pp. 1–3, 2005. View at: Google Scholar
  64. E. Thomas and K. Egon, “Complex interactions between Phytochemicals. The multi-target therapeutic concept of Phytotherapy,” Current Drug Targets, vol. 12, no. 1, pp. 122–132, 2011. View at: Publisher Site | Google Scholar
  65. S. Desagher, A. Osen-Sand, A. Nichols et al., “Bid-induced conformational change of Bax is responsible for mitochondrial cytochrome c release during apoptosis,” Journal of Cell Biology, vol. 144, no. 5, pp. 891–901, 1999. View at: Publisher Site | Google Scholar
  66. J. M. Cain, H. Ngan, S. Garland, and T. Wright, “Control of cervical cancer: women's options and rights,” International Journal of Gynecology and Obstetrics, vol. 106, no. 2, pp. 141–143, 2009. View at: Publisher Site | Google Scholar
  67. G. Campisi, V. Panzarella, M. Giuliani et al., “Human papillomavirus: its identikit and controversial role in oral oncogenesis, premalignant and malignant lesion,” International Journal of Oncology, vol. 30, no. 4, pp. 813–823, 2007. View at: Google Scholar
  68. P. H. Nelson, K. H. Vousden, N. L. Hubbert, D. R. Lowy, and J. T. Schiller, “HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes,” EMBO Journal, vol. 8, no. 12, pp. 3905–3910, 1989. View at: Google Scholar
  69. K. Munger and P. M. Howley, “Human papillomavirus immortalization and transformation functions,” Virus Research, vol. 89, no. 2, pp. 213–228, 2002. View at: Publisher Site | Google Scholar
  70. A. Dasgupta and C. A. Hammet-Stabler, Herbal Supplements: Efficacy, Toxicity, Interactions with Western Drugs and Effects on Clinical Laboratory Tests, John Wiley & Sons, Hoboken, NJ, USA, 2010. View at: Publisher Site
  71. A. G. Cuenca, H. Jiang, S. N. Hochwald, M. Delano, W. G. Cance, and S. R. Grobmyer, “Emerging implications of nanotechnology on cancer diagnostics and therapeutics,” Cancer, vol. 107, no. 3, pp. 459–466, 2006. View at: Publisher Site | Google Scholar
  72. B. Patwardhan, D. Warude, P. Pushpangadan, and N. Bhatt, “Ayurveda and traditional Chinese medicine: a comparative overview,” Evidence-based Complementary and Alternative Medicine, vol. 2, no. 4, pp. 465–473, 2005. View at: Publisher Site | Google Scholar

Copyright © 2012 Anvarbatcha Riyasdeen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles